Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
Citius Oncology reported $5.6 million in net revenue for the first half of fiscal 2026, driven by the commercial launch of LYMPHIR in December 2025, with gross margins of approximately 80%. The company posted a net loss of $26.6 million for Q2, largely due to a $19.7 million one-time charge for a CMO contract cancellation, though R&D expenses declined year-over-year. Subsequent to quarter-end, Citius secured $36.5 million in combined financing via a $25 million debt facility and $11.5 million in warrant exercises, extending its cash runway to November 2026.
Key figures
- Revenue
- 5611409
- Guidance
- Runway extended to November 2026 post-financing
- Revenue Yoy
- N/A (no revenue in prior year)
- Q2 revenue
- 1667298
- H1 net loss
- 32143764
- Q2 net loss
- 26609695
- Q2 ga expenses
- 23625639
- H1 gross margin
- 80%
- H1 gross profit
- 4493323
- Inventory value
- 22659590
- Debt facility size
- 25000000
- Cash and equivalents
- 2632634
- Formulary penetration
- 83%
- Cmo cancellation charge
- 19700000
- Total financing secured
- 36500000
- Warrant exercise proceeds
- 11500000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.